Specified drug use results survey of Stelara in patients with ulcerative colitis

Specified drug use results survey of Stelara in patients with ulcerative colitis - Specified drug use results survey of Stelara in patients with ulcerative colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051601

Enrollment

300

Registered

2023-07-15

Start date

2020-09-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who initiate Stelara for moderate to severe active ulcerative colitis(Only patients who have failed or were intolerant to previous treatment)

Exclusion criteria

Exclusion criteria: Patients with a history of the use of ustekinumab(active ingredient of this product)

Design outcomes

Primary

Measure	Time frame
Safety(ADR) Effectiveness(Partial Mayo Score)	—

Countries

Japan

Contacts

Public ContactMasayuki Takagishi

Janssen Pharmaceutical K.K. Safety Science and Risk Management Dept.

mtakagis@its.jnj.com03-4411-5136

Outcome results